Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
AssigneeBristol-Myers Squibb Company
InventorsJames H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. lwuagwu, F. Christopher Zusi, John E. Macor
Life of this patent
Estimating the term…
Abstract
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Claims4
A pharmaceutical composition comprising a therapeutically effective amount of (R)—N-(6-(1H-imidazol-1-yl)pyrimidin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method for the treatment of schizophrenia, Alzheimer's Disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's Disease, or diabetes comprising administering a therapeutically affective amount of (R)—N-(6-(1H-imidazol-1-yl)pyrimidin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine to a patient.
Dependencies are inferred from the claim text.